View Clinical Trial (Medical Research Study)

Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis - NCT01028781-27599A(Clinical Trial 446676)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Chapel Hill
State:  
NC
Zip Code: 27599
Conditions: Endometriosis
Purpose: Patients will undergo a standard history and physical examination detailing objective clinical exam findings performed by one of the co-investigators. The research coordinator will obtain baseline values for intensity of pain, quality of life, and coping strategies. Baseline serum levels inflammatory markers will then be measured. Over the course of 12 weeks Thalidomide will be titrated as tolerated to achieve a minimum of a 30% reduction of pain on VAS from week 2.
Study summary:
Criteria: Inclusion Criteria: 1. Age > 18 years 2. Histologically/laparoscopically confirmed endometriosis 3. Chronic pelvic pain defined as non-menstrual pain for at least two weeks in the previous month for at least 6 months 4. VAS of 6 or more at baseline 5. Failure, completion or intolerance of standard treatment modalities (oral contraceptive therapy, danazol, Depo-Provera, Depo-Lupron) 6. Patients must give written informed consent. 7. Patients must be willing and able to comply with the FDA-mandated S.T.E.P.S.® program. Exclusion Criteria: 1. Pregnant and/or lactating female 2. Users of other angiogenesis inhibitors 3. Current use of Rifampin, rifabutin, barbiturates, glucocorticoids, phenytoin, carbamazepine, chlorpromazine, reserpine, penicillin derivatives, or St. Johns Wart in user of oral contraceptive therapy 4. Use of aromatase inhibitors, Etanercept (Enbrel), GnRH agonists (Depo-Lupron), and Danazol within the past 3 months 5. Use of norethindrone acetate (Aygestin) in the prior month 6. Seizure disorder 7. Hepatitis, or any active infection (upper respiratory infection, PID, etc) 8. History of thromboembolic disease. 9. Baseline neutropenia (ANC < 1000/mm3) 10. Any severe physical or metal illness that would interfere with the completion of the protocol 11. Illicit drug or alcohol abuse
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: January 6, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.